157. スタージ・ウェーバー症候群 Sturge-Weber syndrome Clinical trials / Disease details


臨床試験数 : 10 薬物数 : 14 - (DrugBank : 4) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 63

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04947124
(ClinicalTrials.gov)
October 19, 20218/6/2021A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101Masked, Randomized, Single-site, Crossover Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 Dosed for 14 Days in Adult Subjects With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)Sturge-Weber Syndrome (SWS);Glaucoma;Glaucoma Congenital;Ocular HypertensionDrug: QLS-101ophthalmic solution 1%;Drug: QLS-101ophthalmic solution 2%Qlaris Bio, Inc.NULLRecruiting18 YearsN/AAll12Phase 2United States
2NCT04999618
(ClinicalTrials.gov)
January 1, 202017/7/2021A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular PathologyDOUBLE-SKIN: a New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology: a Randomised, Double-blind, Placebo-controlled TrialVascular Diseases;Vascular Malformation;Capillary Malformation-Arteriovenous Malformation;Port-Wine Stain;Sturge-Weber Syndrome;Vascular TumorDrug: Haemoblock;Other: PlaceboCenter for Vascular Pathology, MoscowNULLCompleted6 Months18 YearsAll200Phase 4Russian Federation
3NCT04447846
(ClinicalTrials.gov)
October 14, 201910/10/2019Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber SyndromeNovel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome: A Phase II TrialSturge-Weber SyndromeDrug: CannabidiolAnne Comi, MDJazz Pharmaceuticals;Faneca 66 FoundationCompleted3 Years50 YearsAll10Phase 2United States
4NCT03047980
(ClinicalTrials.gov)
January 20172/2/2017Trial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeTrial of Sirolimus for Cognitive Impairment in Sturge-Weber SyndromeSturge-Weber SyndromeDrug: SirolimusAnne Comi, MDChildren's Hospital Medical Center, Cincinnati;Pfizer;National Institutes of Health (NIH);Faneca 66 Foundation;National Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting3 Years31 YearsAll10Phase 2/Phase 3United States
5NCT02332655
(ClinicalTrials.gov)
December 20145/1/2015Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber SyndromeCannabidiol Expanded Access Study in Medically Refractory Sturge-Weber SyndromeSturge-Weber SyndromeDrug: CannabidiolAnne Comi, MDGW Pharmaceuticals Ltd.;Faneca 66 FoundationActive, not recruiting1 Month45 YearsAll5Phase 1/Phase 2United States
6NCT01997255
(ClinicalTrials.gov)
April 201415/11/2013Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber SyndromeSturge Weber SyndromeDrug: EverolimusBaylor College of MedicineNovartis PharmaceuticalsWithdrawn2 Years18 YearsBoth0Phase 2United States
7NCT01533376
(ClinicalTrials.gov)
February 201211/2/2012Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical TimololTreatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical TimololSturge Weber Syndrome;Port-wine MarkDrug: Timolol;Drug: Preservative free artificial tear gel.Wills EyeUniversity of Medicine and Dentistry of New JerseyTerminated2 Years10 YearsAll3Phase 1United States
8EUCTR2010-024078-20-ES
(EUCTR)
11/05/201115/12/2010Ensayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-WeberEnsayo clínico fase II, aleatorizado, triple ciego, controlado intraindividualmente con placebo, para evaluar la eficacia y seguridad de la rapamicina tópica sola o asociada a láser de colorante pulsado en pacientes con síndrome de Sturge-Weber Malformación capilar cutánea en pacientes con síndrome de Sturge-Weber.
MedDRA version: 13;Level: PT;Classification code 10042265;Term: Síndrome de Sturge-Weber
Product Name: Rapamicina tópica al 1% y excipiente
INN or Proposed INN: crema de rapamicina al 1% y excipientes
Product Name: Crema placebo (excipiente)
INN or Proposed INN: Crema placebo (excipiente)
Instituto Científico y Tecnológico de NavarraNULLNot RecruitingFemale: yes
Male: yes
Spain
9NCT02080624
(ClinicalTrials.gov)
January 201118/4/2013Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber SyndromePhase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.Sturge- Weber SyndromeDrug: Drug: Topical RapamycinClinica Universidad de Navarra, Universidad de NavarraNULLCompleted16 Years65 YearsBoth23Phase 2Spain
10NCT00639730
(ClinicalTrials.gov)
May 200614/3/2008Use of the Atkins Diet for Children With Sturge Weber SyndromeUse of the Atkins Diet for Children With Sturge Weber SyndromeEpilepsy;Sturge Weber SyndromeDietary Supplement: modified Atkins dietJohns Hopkins UniversityVascular Birthmarks FoundationCompleted2 Years18 YearsBoth5Phase 1United States